The incidence of serious complications associated with intravitreal therapy in a quaternary ARMD service (2008-2014)

Eye (Basingstoke)

Volumn 29, Issue 1, 2015, Pages 150-

  Severn, P S ^a   Hamilton, R ^a,b  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

AGE RELATED MACULAR DEGENERATION; BLINDNESS; DRUG ADMINISTRATION ROUTE; DRUG INDUCED DISEASE; ENDOPHTHALMITIS; HUMAN; INCIDENCE; INJECTION SITE REACTION; LETTER; OPTICAL COHERENCE TOMOGRAPHY; RETINA DETACHMENT; RETINA TEAR; ADVERSE EFFECTS; GREAT BRITAIN; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; RETINAL DETACHMENT; RETINAL PERFORATIONS; RETROSPECTIVE STUDY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ENDOPHTHALMITIS; GREAT BRITAIN; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; RETINAL DETACHMENT; RETINAL PERFORATIONS; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VITREOUS HEMORRHAGE;

EID: 84920623817     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2014.231     Document Type: Letter

References (2)

1. Attebo K, Mitchell P, Smith W. Visual acuity and the causes of visual loss in Australia: the Blue Mountains Eye Study. Ophthalmology 1996; 103(3): 357-364.
2. National Institute for Health and Care Excellence. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. NICE technology appraisal guidance 155. August 2008. Available at: http://www.nice.org.uk/guidance/ta155.